tatements are not guarantees of future performance. Actual
results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including the
ability to successfully complete the development of new products, execute
agreements required to successfully advance the company's objectives,
retain the scientific management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment,
fluctuations in sales volumes, and realization of intangible assets.
Furthermore, APNB does not intend (and is not obligated) to update publicly
any forward-looking statements. The contents of this news release should be
considered in conjunction with the warnings and cautionary statements
contained in APNB's recent filings with the SEC.
For more information contact:
AspenBio Pharma, Inc.
Gregory Pusey, Chairman
Liolios Group, Inc.
Scott Liolios or Ron Both
AspenBio Pharma, Inc.
Periods Ended June 30, (Unaudited)
Condensed Statements of Operations
(In thousands, except per Three Months Ended Six Months Ended
share data) 2007 2006 2007 2006
Sales $ 177 $ 112 $ 513 $ 348
Gross profit 30 55 195 178
Other revenue - fee - - - 50
Selling, general and
(includes non cash
compensation of $217;
$135; $499 and $189) 632 466 1,358 936
development 544 301 839 612
Operating loss (1,147) (
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
|SOURCE AspenBio Pharma, Inc.|
Copyright©2007 PR Newswire.
. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using
an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier
. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System3
. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors4
. Practical Applications of HyperDSC in a Pharmaceutical Laboratory5
. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition6
. Germantown drug company hires pharma veteran James Davidson as COO7
. Deltanoid Pharmaceuticals begins phase II osteoporosis study8
. New angel capital centered on GenTel agreement with big pharma9
. The deconstruction of Big Pharma10
. Big pharma seeks Wisconsin biotech partnerships11
. Doing the pharmaceutical tango